Economic losses due to low coverage of lipid-lowering therapy in patients with cardiovascular diseases in the Russian Federation

Economic losses due to low coverage of lipid-lowering therapy in patients with cardiovascular diseases in the Russian Federation

Aim. To assess the economic burden associated with the absence of lipid-lowering therapy (LLT) in patients with cardiovascular diseases (CVD) and hypercholesterolemia (HCS) in the Russian population in 2016, including direct costs of the health care system and indirect economic losses due to premat...

Full description

Bibliographic Details
Main Authors:	Yu. A. Balanova, A. V. Kontsevaya, A. E. Imaeva, O. I. Karpov, M. B. Khudyakov
Format:	Article
Language:	English
Published:	Столичная издательская компания 2018-11-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	low lipid-lowering therapy coverage prevalence of hypercholesterolemia economic burden associated with the absence of lipid-lowering therapy
Online Access:	https://www.rpcardio.online/jour/article/view/1761

Similar Items

Alirocoumab: new perspectives of lipid-lowering therapy
by: Zh D Kobalava, et al.
Published: (2017-12-01)

EFFICACY AND SAFETY OF LIPID-LOWERING DRUGS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE ELDERLY
by: E. A. Ushkalova, et al.
Published: (2016-06-01)

Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia
by: Anselm K. Gitt, et al.
Published: (2022-06-01)

Homozygous familial hypercholesterolemia: modern aspects of pathogenesis, diagnostics and treatment
by: V. К. Zafiraki, et al.
Published: (2018-10-01)

ECONOMIC BURDEN OF HYPERCHOLESTEROLEMIA IN THE RUSSIAN FEDERATION
by: A. V. Kontsevaya, et al.
Published: (2018-07-01)

How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment
by: Sibbeliene E. van den Bosch, et al.
Published: (2023-03-01)

Clinical Features of Familial Hypercholesterolemia in Children and Adults in EAS-FHSC Regional Center for Rare Diseases in Poland
by: Joanna Lewek, et al.
Published: (2021-09-01)

PCSK9: A New Target for Lipid-Lowering Therapy
by: Nutjaree Jeenduang
Published: (2014-04-01)

FAMILIAL HYPERCHOLESTEROLEMIA: DIAGNOSTIC ISSUES AND THERAPEUTIC POSSIBILITIES
by: Vitalii K. Zafiraki, et al.
Published: (2019-03-01)

Comparative Efficacy and Safety of Statin Monotherapy and Statin plus Ezetimibe Combination in a Real-World Setting
by: Marat V. Ezhov, et al.
Published: (2023-11-01)

Familial Hypercholesterolemia: Pitfalls and Challenges in Diagnosis and Treatment
by: Natalie Arnold, et al.
Published: (2023-08-01)

Clinical management of heterozygous familial hypercholesterolemia in a Polish outpatient metabolic clinic: a retrospective observational study
by: Longina Kłosiewicz-Latoszek, et al.
Published: (2017-11-01)

Management of hypercholesterolemia, appropriateness of therapeutic approaches and new drugs in patients with high cardiovascular risk
by: Roberto Vettor, et al.
Published: (2018-09-01)

Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
by: Nagham N. Hindi, et al.
Published: (2021-08-01)

Analysis of the frequency of detection of hypercholesterolemia, carotid atherosclerosis and lipid-lowering therapy prescription in young adults under 45 years old according to the Duplex registry database
by: Oleg V. Gaisenok
Published: (2023-03-01)

Spectrum of cardiovascular manifestations in homozygous familial hypercholesterolemia
by: Nitin Bajaj, et al.
Published: (2023-01-01)

The role of soluble fiber intake in patients under highly effective lipid-lowering therapy
by: Rezende Vinicius M, et al.
Published: (2011-08-01)

Secondary Prevention in Lower Extremity Artery Disease Patients: Lipid-Lowering Therapy and Long-Term Guideline Adherence
by: Linda Mueller, et al.
Published: (2022-11-01)

MEDICAL SUPERVISION IN SPECIALIZED CENTER AND THE QUALITY OF LIPID-LOWERING THERAPY IN PATIENTS WITH CARDIOVASCULAR DISEASES (ACCORDING TO THE PROFIL REGISTER)
by: S. Yu. Martsevich, et al.
Published: (2015-09-01)

Exploring Contemporary Data on Lipid-Lowering Therapy Prescribing in Patients Following Discharge for Atherosclerotic Cardiovascular Disease in the South of Italy
by: Anna Citarella, et al.
Published: (2022-07-01)

Assessment of lipid profile when using lipid-lowering therapy (statins) in patients with coronary atherosclerosis
by: N. E. Gavrilova, et al.
Published: (2015-11-01)

Gene transfer and genome editing for familial hypercholesterolemia
by: Cesare Canepari, et al.
Published: (2023-04-01)

Rationale and design of the Hellenic Registry of Clinical events and Adherence to Lipid LowerINg therapy In aCUte coronary Syndrome (CALLINICUS-Hellas Registry)
by: Loukianos S. Rallidis, et al.
Published: (2022-07-01)

The Progression of Treatment for Refractory Hypercholesterolemia: Focus on the Prospect of Gene Therapy
by: Zhi-Fan Li, et al.
Published: (2022-06-01)

Appointment of lipid-lowering therapy in the Russian population: comparison of SCORE and SCORE2 (according to the ESSE-RF study)
by: A. M. Erina, et al.
Published: (2022-06-01)

2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
by: Maciej Banach, et al.
Published: (2023-11-01)

ANICHKOV study: the effect of combined hypotensive and lipid-lowering therapy on cardiovascular complications in patients of high and very high risk
by: I V Sergienko, et al.
Published: (2019-04-01)

Modern possibilities of intensive treatment of dyslipidemia and gaps in its control: literature review
by: Vera N. Larina, et al.
Published: (2023-04-01)

Status of lipid control in Bangladeshi subjects with type 2 diabetes mellitus on lipid-lowering drugs: a multicenter, facility-based, cross-sectional study
by: Shahjada Selim, et al.
Published: (2023-12-01)

Unsolved Issues of Atherosclerosis Prevention and of Adequate Lipid-lowering Therapy in Patients with Acute Ischemic Cerebrovascular Accident
by: S. A. Boytsov, et al.
Published: (2022-01-01)

Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association
by: Maciej Banach, et al.
Published: (2023-11-01)

Non adherence to lipid-lowering therapy and strategies to improve adherence
by: Ashwani Mehta
Published: (2024-03-01)

MODERN ASPECTS OF LIPID LOWERING THERAPY: FOCUS ON INFLAMMATION
by: I. A. LIBOV, et al.
Published: (2016-12-01)

Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline
by: Chibuike J. Alanaeme, et al.
Published: (2022-09-01)

IDENTIFICATION OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA IN THE RUSSIAN POPULATION USING THE EXAMPLE OF MOSCOW CITY AND MOSCOW REGION
by: I. V. Sergienko, et al.
Published: (2018-03-01)

New reimbursement criteria for lipid-lowering drugs
by: Mario Eandi
Published: (2011-06-01)

Advances in Pharmacological Approaches for Managing Hypercholesterolemia: A Comprehensive Overview of Novel Treatments
by: Andrea Mormone, et al.
Published: (2024-02-01)

Cataract Surgery in Elderly Subjects with Heterozygous Familial Hypercholesterolemia in Prolonged Treatment with Statins
by: Victoria Marco-Benedí, et al.
Published: (2021-08-01)

Current Treatment Options in Homozygous Familial Hypercholesterolemia
by: Meral Kayikcioglu, et al.
Published: (2022-12-01)

Cholesterol: Controversies and consensus over 100 years of persistent efforts
by: Shui-Ping Zhao
Published: (2017-01-01)